A randomized controlled trial of sequential peginterferon-alpha and telbivudine or vice versa for 48 weeks in HBeAg-negative chronic hepatitis B

Trial Profile

A randomized controlled trial of sequential peginterferon-alpha and telbivudine or vice versa for 48 weeks in HBeAg-negative chronic hepatitis B

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2012

At a glance

  • Drugs Peginterferon alfa (Primary) ; Telbivudine (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top